Literature DB >> 30429006

Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.

Joan E Walter1, Marjolein A Heuvelmans2, Geertruida H de Bock3, Uraujh Yousaf-Khan4, Harry J M Groen5, Carlijn M van der Aalst4, Kristiaan Nackaerts6, Peter M A van Ooijen1, Harry J de Koning4, Rozemarijn Vliegenthart1, Matthijs Oudkerk7.   

Abstract

BACKGROUND: New nodules are regularly found after the baseline round of low-dose computed tomography (LDCT) lung cancer screening. The relationship between a participant's number of new nodules and lung cancer probability is unknown.
METHODS: Participants of the ongoing Dutch-Belgian Randomized Lung Cancer Screening (NELSON) Trial with (sub)solid nodules detected after baseline and registered as new by the NELSON radiologists were included. The correlation between a participant's new nodule count and the largest new nodule size was assessed using Spearman's rank correlation. To evaluate the new nodule count as predictor for new nodule lung cancer together with largest new nodule size, a multivariable logistic regression analysis was performed.
RESULTS: In total, 705 participants with 964 new nodules were included. In 48% (336/705) of participants no nodule had been found previously during baseline screening and in 22% (154/705) of participants >1 new nodule was detected (range 1-12 new nodules). Eventually, 9% (65/705) of the participants had lung cancer in a new nodule. In 100% (65/65) of participants with new nodule lung cancer, the lung cancer was the largest or only new nodule at initial detection. The new nodule lung cancer probability did not differ significantly between participants with 1 (10% [56/551], 95%CI 8-13%) or >1 new nodule (6% [9/154], 95%CI 3-11%, P = .116). An increased number of new nodules positively correlated with a participant's largest nodule size (P < 0.001, Spearman's rho 0.177). When adjusted for largest new nodule size, the new nodule count had a significant negative association with lung cancer (odds ratio 0.59, 0.37-0.95, P = .03).
CONCLUSION: A participant's new nodule count alone only has limited association with lung cancer. However, a higher new nodule count correlates with an increased largest new nodule size, while the lung cancer probability remains equivalent, and may improve lung cancer risk prediction by size only.
Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Early detection of cancer; Incidence screening; Lung neoplasms; Multiple pulmonary nodules

Mesh:

Year:  2018        PMID: 30429006     DOI: 10.1016/j.lungcan.2018.05.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  14 in total

Review 1.  Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.

Authors:  Matthijs Oudkerk; ShiYuan Liu; Marjolein A Heuvelmans; Joan E Walter; John K Field
Journal:  Nat Rev Clin Oncol       Date:  2020-10-12       Impact factor: 66.675

2.  Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis.

Authors:  Attila Nagy; Veronika Müller; Abigel M Kolonics-Farkas; Noemi Eszes; Krisztina Vincze; Gabor Horvath
Journal:  Thorac Cancer       Date:  2019-07-17       Impact factor: 3.500

Review 3.  Implementation of lung cancer screening: what are the main issues?

Authors:  Carlijn M van der Aalst; Kevin Ten Haaf; Harry J de Koning
Journal:  Transl Lung Cancer Res       Date:  2021-02

4.  Challenges of Implementing Lung Cancer Screening in a Developing Country: Results of the Second Brazilian Early Lung Cancer Screening Trial (BRELT2).

Authors:  Bruno Hochhegger; Spencer Camargo; Gustavo Borges da Silva Teles; Rodrigo Caruso Chate; Gilberto Szarf; Marcos Duarte Guimarães; Jefferson Luiz Gross; Paula Nicole Vieira Pinto Barbosa; Rodrigo Sampaio Chiarantano; Rui Manuel Reis; Edmundo Carvalho Mauad; Mario Ghefter; Petrucio Sarmento; Raphael Pereira; José Rocha; Marcel Lima Albuquerque; André Miotto; Daniela Cristina Almeida Dias; Juliana P Franceschini; Hiran C Fernando; Ricardo Sales Dos Santos
Journal:  JCO Glob Oncol       Date:  2022-01

5.  Circular RNA UBR1 promotes the proliferation, migration, and invasion but represses apoptosis of lung cancer cells via modulating microRNA-545-5p/SSFA2 axis.

Authors:  Peng Su; Feng Mao; Jian Zhang; Hui Zhang; MingBo Wang; YanZhao Xu; ZiQiang Tian
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.

Authors:  Masaoki Ito; Yoshihiro Miyata; Shoko Hirano; Fumiko Irisuna; Kei Kushitani; Yuichiro Kai; Naoto Kishi; Yasuhiro Tsutani; Yukio Takeshima; Morihito Okada
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-03       Impact factor: 4.553

7.  Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer.

Authors:  Feng Xu; Jian Song; Beizheng Xu; Jiang Wang; Jianjun Mao; Haiyan Liu; Xuanmei Li; Aibing Deng
Journal:  BMC Cancer       Date:  2020-11-11       Impact factor: 4.430

8.  5-aza-2'-deoxycytidine (DAC) treatment induces the MAGE-A10 expression and improves the cytotoxicity of MAGE-A10-specific CTLs in lung cancer cells.

Authors:  Zhenhua Li; Peng Guo; Peiyuan Guo; Keqin Dong; Fei Liu; Yunyan Wu; Juan Li; Baoen Shan; Meixiang Sang
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

9.  Executive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck
Journal:  Chest       Date:  2021-07-13       Impact factor: 9.410

10.  Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck
Journal:  Chest       Date:  2021-07-13       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.